A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

NCT04025216 PHASE1 TERMINATED

Multi-center, open-label, first in human Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CART- TnMUC1 cells).

Details

Lead sponsor	Kite, A Gilead Company
Phase	PHASE1
Status	TERMINATED
Enrolment	16
Start date	Thu Oct 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Dec 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Non-Small Cell Lung Cancer
• Ovarian Cancer
• Fallopian Tube Cancer
• Triple Negative Breast Cancer
• Multiple Myeloma
• Pancreatic Ductal Adenocarcinoma

Interventions

• CART-TnMUC1
• Cyclophosphamide
• Fludarabine

Countries

United States